US 12,448,380 B2
Positive modulators of the muscarinic acetylcholine receptor M4
Craig W. Lindsley, Brentwood, TN (US); Darren W. Engers, Brentwood, TN (US); Kayla J. Temple, Spring Hill, TN (US); Alison R. Gregro, Mount Juliet, TN (US); Alexa E. Richardson, Nashville, TN (US); and Madeline F. Long, Nashville, TN (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on Dec. 26, 2024, as Appl. No. 19/002,103.
Application 19/002,103 is a continuation of application No. 18/750,829, filed on Jun. 21, 2024.
Claims priority of provisional application 63/610,220, filed on Dec. 14, 2023.
Claims priority of provisional application 63/509,589, filed on Jun. 22, 2023.
Prior Publication US 2025/0122199 A1, Apr. 17, 2025
Int. Cl. C07D 471/04 (2006.01); A61K 31/4545 (2006.01); C07B 59/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/4545 (2013.01); C07B 59/002 (2013.01)] 8 Claims
 
1. A method of treating a neurological, psychiatric, or cognitive disorder associated with the mAChR M4 receptor, comprising administering Compound 3, having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, to a subject in need thereof.